Skip to main content

Table 1 Baseline characteristics and clinical data

From: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

VariableAll subjectsStable groupProgression groupP-value
(n = 49)(n = 32)(n = 17)
Sex M/F (n)38/1124/814/30.56
Age (yr)69 (65–75)70 (66–76)68 (64–75)0.38
Smokers/never-smokers (n)36/1323/913/40.73
Pack-years smoking30 (0.8–51.5)34 (5–52.1)25 (0.8–49.5)0.61
BMI23.8 (22.1–25.8)23.6 (22.1–25.5)25.0 (21.7–26.1)0.43
GAP stage (n), I/II/III20/24/514/15/36/9/20.84
FVC (L)2.42 (2.08–2.86)2.40 (2.09–3.65)2.64 (2.02–2.78)0.83
% FVC (%)76.6 (65.4–92.5)77.4 (65.1–94.4)76.6 (66.4–86.9)0.78
DLco (mL/min/mmHg)10.7 (9.22–13.5)10.6 (9.25–13.5)10.7 (8.81–14.3)0.76
% DLco (%)52.8 (44.3–59.8)52.8 (44.4–57.6)51.7 (43.6–70.3)0.97
PaO2 at rest (Torr)82.7 (78.2–88.6)81.5 (77.2–91.6)83.8 (78.4–87.3)0.71
Minimum SpO2 during 6MWT (%)91 (87.3–93)91 (88–93)90 (85.5–93)0.42
6MWT Distance (meter)410 (380–480)420 (385–480)400 (360–490)0.94
SP-A (ng/mL)57.8 (41.7–79.1)60.3 (42.6–76.1)56.6 (40.6–96.7)0.83
SP-D (ng/mL)243 (181–352)241 (177–357)246 (166–350)0.97
KL-6 (U/mL)901 (663–1494)885 (595.3–1618)901 (732–1336)0.44
pirfenidone/nintedanib23/2617/156/110.23
Treatment history of anti-fibrotic drug (n), yes/no7/424/283/140.66
  1. Data are expressed as frequencies or medians (interquartile range). P-value: stable group vs. progression group.
  2. BMI body mass index; GAP (gender [G], age [A], and 2 lung physiology variables [P] [FVC and DLco]); FVC forced vital capacity; DLco diffusing capacity of the lung for carbon monoxide; PaO2 partial pressure of arterial oxygen; SpO2 arterial oxygen saturation measured by pulse oximetry; 6MWT 6 min-walk test; SP surfactant protein; KL-6 Krebs von den Lungen-6